Commenting on media reports on the imminent approval of its Alzheimer's disease (AD) drug lecanemab in the UK, BioArctic AB (BRCTF) said, "BioArctic has currently not been informed that the relevant authorities have made a decision and cannot therefore comment on these rumors."
In 2007, Eisai secured global rights from BioArctic to study, develop, manufacture and market lecanemab for the treatment of AD. Later, Eisai and Biogen jointly developed the drug under the collaboration agreement signed in 2014.
Results from the Phase 3 study showed that the treatment with lecanemab slowed cognitive decline by 27 percent in AD patients.
Lecanemab, marketed as leqembi is already approved in countries including the U.S., Japan, and China for the treatment of AD.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.